Patients with moderate CKD (estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m2) treated with the IL-1β selective antagonist canakinumab demonstrated a significantly reduced risk of MACE. Here, IL1B is linked to chronic kidney disease.